The stock of NanoString Technologies Inc (NASDAQ:NSTG) is a huge mover today! About 116,027 shares traded hands. NanoString Technologies Inc (NASDAQ:NSTG) has risen 33.33% since March 8, 2016 and is uptrending. It has outperformed by 24.02% the S&P500.
The move comes after 8 months negative chart setup for the $440.42 million company. It was reported on Oct, 11 by Barchart.com. We have $18.67 PT which if reached, will make NASDAQ:NSTG worth $52.85M less.
Analysts await NanoString Technologies Inc (NASDAQ:NSTG) to report earnings on November, 7. They expect $-0.51 earnings per share, down 4.08% or $0.02 from last year’s $-0.49 per share. After $-0.55 actual earnings per share reported by NanoString Technologies Inc for the previous quarter, Wall Street now forecasts -7.27% EPS growth.
According to Zacks Investment Research, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 2.52 in Q2 2016. Its up 1.31, from 1.21 in 2016Q1. The ratio is positive, as 9 funds sold all NanoString Technologies Inc shares owned while 12 reduced positions. 15 funds bought stakes while 38 increased positions. They now own 16.55 million shares or 3.90% more from 15.93 million shares in 2016Q1.
Cormorant Asset Management Ltd Liability has 0.07% invested in the company for 40,490 shares. National Bank & Trust Of New York Mellon Corp holds 0% or 97,569 shares in its portfolio. Driehaus Cap Management Ltd Llc last reported 0.08% of its portfolio in the stock. Fred Alger last reported 0% of its portfolio in the stock. Blackrock Fund Advsr has invested 0% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG). Strs Ohio, a Ohio-based fund reported 31,900 shares. The California-based Schwab Charles Mgmt Inc has invested 0% in NanoString Technologies Inc (NASDAQ:NSTG). Deutsche Commercial Bank Ag owns 5,994 shares or 0% of their US portfolio. Tfs Capital Limited Liability holds 0.06% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG) for 26,384 shares. Deerfield Mgmt holds 674,622 shares or 0.33% of its portfolio. Acadian Asset Mngmt Ltd Liability has invested 0% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG). Moreover, Wells Fargo And Company Mn has 0% invested in NanoString Technologies Inc (NASDAQ:NSTG) for 7,749 shares. Geode Cap Mngmt Lc last reported 0% of its portfolio in the stock. Manufacturers Life Insurance The, a Ontario – Canada-based fund reported 11,739 shares. Pier Capital Ltd Limited Liability Company holds 0.46% or 202,405 shares in its portfolio.
Insider Transactions: Since August 12, 2016, the stock had 0 insider buys, and 6 sales for $8.52 million net activity. WAITE CHARLES P JR sold $1.20M worth of stock. BURNS WAYNE sold $65,357 worth of NanoString Technologies Inc (NASDAQ:NSTG) on Wednesday, September 7.
NSTG Company Profile
NanoString Technologies, Inc., incorporated on June 20, 2003, develops, makes and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Firm operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Firm markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use. The Company’s molecular diagnostic product Prosigna Breast Cancer Assay, or Prosigna, provides an assessment of a patient’s risk of recurrence for breast cancer. The Firm has an installed base of over 350 systems, which its clients have used to publish more than 1,000 peer-reviewed papers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.